REGENERON PHARMACEUTICALS, INC for REGENERON PHARMACEUTICALS, INC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers
| Lobbyist | Covered position, as disclosed |
|---|---|
| MADDIE DAVIDSON | — |
| EBEN DUROSS | — |
| KATHERINE HADDAD | — |
| VALERIE VOLPE | — |
Copyright/Patent/Trademark CPT
Patent issues relating to biopharmaceutical manufacturers; intellectual property rights; issues related to WTO TRIPS waivers
| Lobbyist | Covered position, as disclosed |
|---|---|
| MADDIE DAVIDSON | — |
| EBEN DUROSS | — |
| VALERIE VOLPE | — |
Health Issues HCR
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; Consolidated Appropriations Act, 2023; issues related to the Prescription Drug User Fee Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| MAYA BERMINGHAM | — |
| MADDIE DAVIDSON | — |
| EBEN DUROSS | — |
| KATHERINE HADDAD | — |
| VALERIE VOLPE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.